Number of qualified people: CDEC mentioned the uncertainty in the volume of patients with moderately intense to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some patients who're labeled as possessing gentle or moderate condition might have a extreme bleeding phenotype, which https://knoxqwzab.topbloghub.com/42335087/the-smart-trick-of-hemgenix-that-nobody-is-discussing